Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

Soochow University

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Acute Leukemia in Remission; Platelet Transfusion Refractoriness

Treatments: Biological: CAR-T infusion

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04846439

2021062

Details and patient eligibility

About

Alloimmune-mediated platelet transfusion refractoriness(PTR) was usually caused by repeated blood transfusions and pregnancy and accounts for about 20-25% of PTR patients. Patients with acute leukemia need repeated platelet infusion in myelosuppression period after chemotherapy, and PTR incidence is more higher.PTR was associated with adverse events,including longer hospital stays,severe hemorrhages and an increased risk of early deaths and may have a negative impact on the success of HSCT. The current management of patients with PTR includes specific transfusion strategies, IVIG, rituximab,thrombopoietin-receptor agonists(TPO-RA) ,bortezomib or splenectomy,have been largely unsatisfactory. As we know, HLA antibodies are mainly secreted by the plasma cells. Researchers want to see if sequential infusion of CD19 and BCMA CAR-T cells can clear the B cells and plasma cells, can help increase platelet levels and reduce bleeding in patients with platelet transfusion refractoriness. To see if sequential infusion can increases platelet levels more after a transfusion. To see if it reduces the chance of bleeding. Adults 16-65 years old who diagnosed with acute leukemia in CR and alloimmune platelet transfusion refractoriness.

Full description

The patients will receive infusion of CAR T-cells targeting CD19 and BCMA to confirm the safety and efficacy of CD19 and BCMA CAR T-Cells Sequential infusion in acute leukemia with alloimmune-mediated platelet transfusion refractoriness.

Enrollment: 20 estimated patients

Sex: All

Ages: 16 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ages 16-65 years inclusive.
• Ability to comprehend the investigational nature of the study and provide informed consent.
• Expected survival time ≥ 3 months (according to investigator's judgement)
• Acute leukemia in complete remission diagnosed with alloimmune-mediated PTR, characterized by all of the following:

Lack of adequate post-transfusion platelet count increment, defined by CCI <7500/μl at 10-60 min, and CCI <5000/μl at 18-24 hrs (in those who had a CCI at 10-60 min greater than or equal to 5000/μl) after at least 2 consecutive transfusions.

Presence of anti-HLA class A and/or B antibody.

• Left ventricular ejection fractions ≥ 0.5 by echocardiography.
• Creatinine < 1.6 mg/dL.
• Aspartate aminotransferase/aspartate aminotransferase < 3x upper limit of normal.
• Total bilirubin <2.0 mg/dL.
• karnofsky performance status ≥ 60.

Exclusion criteria

• PTR induced by other reasons(eg:DIC,fever,infection and splenomegaly)
• Uncontrolled active infection.
• Active hepatitis B or hepatitis C infection
• Patients with HIV or syphilis infection
• Patients are pregnant or lactating
• Patients has a history of allo-HSCT
• Alloimmune-mediated PTR responsive to treatment with plasma exchange
• Alloimmune-mediated PTR responsive to treatment with rituximab or IVIG
• Grade III/IV cardiovascular disability according to the New York Heart Association Classification
• Patients with other contraindications considered unsuitable for participation in this study (according to investigator's judgement)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

CAR-T infusion

Experimental group

Description:

CD19 and BCMA CAR-T cells were infused into complete remission acute leukemia patients with PTR sequentially, with（1.0-2.0）×10e7/kg respectively. Each patient was followed up for 1 years.

Treatment:

Biological: CAR-T infusion